FDA lifts partial hold on Forum's encenicline

Forum Pharmaceuticals Inc. (Waltham, Mass.) said FDA lifted a partial clinical hold on a long-term Phase III extension trial of encenicline ( EVP-6124) to treat cognitive impairment in schizophrenia (CIS).

FDA placed the hold in September. Forum had said a "very small number" of serious gastrointestinal-related safety events were observed in Alzheimer's disease studies. A hold remains in place on trials of encenicline to treat AD (see BioCentury Extra, Sept. 14). ...